lymphoma

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo

Timothy Illidge Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 TIMOTHY ILLIDGE, Christie Hospital, Manchester Radioconjugated antibodies are showing grea

Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free surv

Christian Geisler CHRISTIAN GEISLER, Rigshospitalet, Copenhagen Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek T

Francis Giles Ken Kaushansky Heather Leitch Nancy Berliner Corrado Tarella Vincent Rajkumar Robert Kyle Aurora Kinase BCR-ABL Inhibitor Beats T315-I Mutation in Patients with Chronic Myeloid Leukemia

Martin Müller Charles Linker Andreas Hochhaus Christian Buske Katarina Le Blanc Stephen Emerson Alessandro Vannucchi Kanti Rai Richard Schlenk BCR-ABL Mutations After Imatinib Failure: Impact on Respo

George Canellos Sandra Strauss Nancy Baxter KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse Risk Liver Metastasis Resection Not Curative for Colorectal Cancer Patients With Node Negative

Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therap

Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH